R&D Impact May Be Key In Scrutiny Of Pfizer Oncology Deal
U.S. pharmaceutical giant Pfizer's planned $14 billion acquisition of oncology biotech Medivation could sail through an antitrust review given their minimal product overlaps, unless regulators opt to heighten their focus on...To view the full article, register now.
Already a subscriber? Click here to view full article